公司資料
PureTech Health 股價、新聞與催化劑
- 股票代碼:
- PRTC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom
股票表現
17.42 USD (+1.99%)
收盤價
最後更新: 2026年5月20日
424M USD
市值
股價為何變動
Current closing-price context is not available for PRTC.
公司概覽
Founded-Entity Model
PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities.
Celea Therapeutics
Celea is developing deupirfenidone, formerly LYT-100, for idiopathic pulmonary fibrosis. The deuterated pirfenidone candidate completed the Phase 2b ELEVATE IPF study and is Phase 3 ready for the head-to-head SURPASS-IPF trial against pirfenidone.
Gallop Oncology
Gallop is advancing LYT-200, an anti-galectin-9 antibody, for relapsed or refractory myeloid malignancies. Phase 1b data in high-risk myelodysplastic syndrome and acute myeloid leukemia provide clinical validation for a planned next stage of development.
Seaport Therapeutics
Seaport applies the Glyph platform to neuropsychiatric medicines designed for lymphatic transport and enhanced exposure. Its pipeline includes GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder and associated sleep disturbance.
Portfolio Value Creation
PureTech seeks to create value by separating programs into focused companies, attracting external capital and partners, and retaining equity or contractual economics. This structure allows different assets to progress with dedicated management and financing.
未來催化劑
- Initiation of Celea’s Phase 3 SURPASS-IPF trial near the closing of its planned financing.
- Topline Phase 2b BUOY-1 data for GlyphAllo expected in the first half of 2027.
- Phase 2a GlyphAgo sleep-study results expected in early 2028 and Phase 2b GAD results expected by year-end 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。